Kiniksa Pharmaceuticals International, plc Class A KNSA

Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a little, with the share price down over the past month. However, the 90 day share price return of 33.73% and year to date gain of 81.12% point to a strong upswing overall. Compare Kiniksa...

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximatel

Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 net product revenue guidance to a range of US$980 million to US$995 million after releasing second quarter results and updating investors on its pipeline. See our latest analysis for Kiniksa Pharmaceuticals International. The raised 2026 guidance and strong second quarter update follow a sharp move in Kiniksa Pharmaceuticals International's stock, with an 8.1x five year total shareholder return and a 92.6% year to date share...

Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to US$945 million. Beyond the headline growth, the company’s upgraded outlook and progress on its cardiovascular pipeline, including the Phase 3 program for KPL-387 in recurrent pericarditis, highlight...

Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q2 2026 earnings call

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported strong second-quarter 2026 financial results, raised its full-year ARCALYST sales guidance, and advanced its cardiovascular pipeline with the Phase 3 launch of KPL-387 for recurrent pericarditis. Key Investor TakeawaysKiniksa increased its 2026 ARCALYST net sales guidance to $980 million-$995 million following strong prescription growth and higher patient adoption.

– ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –– Conference call and webcast scheduled for 8:30 am ET toda